JP7237386B2 - メロキシカムおよびリザトリプタンを含有する組み合わせの使用 - Google Patents

メロキシカムおよびリザトリプタンを含有する組み合わせの使用 Download PDF

Info

Publication number
JP7237386B2
JP7237386B2 JP2021545919A JP2021545919A JP7237386B2 JP 7237386 B2 JP7237386 B2 JP 7237386B2 JP 2021545919 A JP2021545919 A JP 2021545919A JP 2021545919 A JP2021545919 A JP 2021545919A JP 7237386 B2 JP7237386 B2 JP 7237386B2
Authority
JP
Japan
Prior art keywords
meloxicam
rizatriptan
migraine
hours
dosage form
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2021545919A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022519670A (ja
Inventor
タビュトー、ヘリオット
Original Assignee
アクスサム セラピューティクス インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by アクスサム セラピューティクス インコーポレイテッド filed Critical アクスサム セラピューティクス インコーポレイテッド
Publication of JP2022519670A publication Critical patent/JP2022519670A/ja
Priority to JP2023025218A priority Critical patent/JP7420990B2/ja
Application granted granted Critical
Publication of JP7237386B2 publication Critical patent/JP7237386B2/ja
Priority to JP2024002855A priority patent/JP2024026732A/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4196—1,2,4-Triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/5415—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with carbocyclic ring systems, e.g. phenothiazine, chlorpromazine, piroxicam
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/40—Cyclodextrins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6949—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes
    • A61K47/6951—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes using cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Inorganic Chemistry (AREA)
  • Neurosurgery (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Cosmetics (AREA)
JP2021545919A 2019-02-06 2020-02-06 メロキシカムおよびリザトリプタンを含有する組み合わせの使用 Active JP7237386B2 (ja)

Priority Applications (2)

Application Number Priority Date Filing Date Title
JP2023025218A JP7420990B2 (ja) 2019-02-06 2023-02-21 メロキシカムおよびリザトリプタンを含有する組み合わせの使用
JP2024002855A JP2024026732A (ja) 2019-02-06 2024-01-11 メロキシカムおよびリザトリプタンを含有する組み合わせの使用

Applications Claiming Priority (17)

Application Number Priority Date Filing Date Title
US201962802198P 2019-02-06 2019-02-06
US62/802,198 2019-02-06
US201962803756P 2019-02-11 2019-02-11
US62/803,756 2019-02-11
US201962835613P 2019-04-18 2019-04-18
US62/835,613 2019-04-18
US201962846311P 2019-05-10 2019-05-10
US62/846,311 2019-05-10
US201962860705P 2019-06-12 2019-06-12
US62/860,705 2019-06-12
US201962895933P 2019-09-04 2019-09-04
US201962895956P 2019-09-04 2019-09-04
US62/895,956 2019-09-04
US62/895,933 2019-09-04
US201962955905P 2019-12-31 2019-12-31
US62/955,905 2019-12-31
PCT/US2020/017046 WO2020163620A1 (fr) 2019-02-06 2020-02-06 Compositions pharmaceutiques comprenant du méloxicam

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2023025218A Division JP7420990B2 (ja) 2019-02-06 2023-02-21 メロキシカムおよびリザトリプタンを含有する組み合わせの使用

Publications (2)

Publication Number Publication Date
JP2022519670A JP2022519670A (ja) 2022-03-24
JP7237386B2 true JP7237386B2 (ja) 2023-03-13

Family

ID=71947112

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2021545919A Active JP7237386B2 (ja) 2019-02-06 2020-02-06 メロキシカムおよびリザトリプタンを含有する組み合わせの使用
JP2023025218A Active JP7420990B2 (ja) 2019-02-06 2023-02-21 メロキシカムおよびリザトリプタンを含有する組み合わせの使用
JP2024002855A Pending JP2024026732A (ja) 2019-02-06 2024-01-11 メロキシカムおよびリザトリプタンを含有する組み合わせの使用

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2023025218A Active JP7420990B2 (ja) 2019-02-06 2023-02-21 メロキシカムおよびリザトリプタンを含有する組み合わせの使用
JP2024002855A Pending JP2024026732A (ja) 2019-02-06 2024-01-11 メロキシカムおよびリザトリプタンを含有する組み合わせの使用

Country Status (17)

Country Link
EP (1) EP3920909A4 (fr)
JP (3) JP7237386B2 (fr)
KR (1) KR20210118880A (fr)
CN (1) CN113423397A (fr)
AU (2) AU2020218253B2 (fr)
BR (1) BR112021015467A2 (fr)
CA (2) CA3213549A1 (fr)
CL (1) CL2021002070A1 (fr)
CO (1) CO2021010380A2 (fr)
CR (1) CR20210420A (fr)
EC (1) ECSP21060962A (fr)
IL (1) IL285389A (fr)
MA (1) MA54904A (fr)
MX (1) MX2021009435A (fr)
PE (1) PE20212157A1 (fr)
SG (1) SG11202107926XA (fr)
WO (1) WO2020163620A1 (fr)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2021414212A1 (en) * 2020-12-31 2023-07-20 Axsome Therapeutics, Inc. Pharmaceutical compositions comprising meloxicam

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2002528498A (ja) 1998-11-02 2002-09-03 メルク エンド カムパニー インコーポレーテッド 片頭痛の治療方法及び医薬組成物
JP2012526849A (ja) 2009-05-13 2012-11-01 サイデックス・ファーマシューティカルズ・インコーポレイテッド プラスグレル及びシクロデキストリン誘導体を含む医薬組成物並びにその製造方法及び使用方法
JP2018508570A (ja) 2015-11-25 2018-03-29 アクスサム セラピューティクス インコーポレイテッド メロキシカムを含む医薬組成物
WO2018129220A1 (fr) 2017-01-04 2018-07-12 Axsome Therapeutics, Inc. Compositions pharmaceutiques contenant du méloxicam
WO2018209150A1 (fr) 2017-05-10 2018-11-15 Axsome Therapeutics, Inc. Compositions pharmaceutiques contenant du méloxicam

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040214861A1 (en) * 2003-03-28 2004-10-28 Pharmacia Corporation Compositions of a cyclooxygenase-2 selective inhibitors and 5-HT1B1D antagonists for the treatment and prevention of migraine
US8268791B2 (en) * 2004-08-25 2012-09-18 Aegis Therapeutics, Llc. Alkylglycoside compositions for drug administration
US20090068262A1 (en) * 2007-04-04 2009-03-12 Ilan Zalit Rapid dissolution of combination products
WO2016131067A2 (fr) * 2015-02-10 2016-08-18 Antecip Bioventures Ii Llc Compositions pharmaceutiques contenant du méloxicam
US9821075B2 (en) * 2015-02-10 2017-11-21 Axsome Therapeutics, Inc. Pharmaceutical compositions comprising meloxicam
KR20220031944A (ko) * 2016-09-23 2022-03-14 테바 파마슈티컬스 인터내셔널 게엠베하 불응성 편두통의 치료
US10471014B2 (en) * 2017-01-04 2019-11-12 Axsome Therapeutics, Inc. Pharmaceutical compositions comprising meloxicam

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2002528498A (ja) 1998-11-02 2002-09-03 メルク エンド カムパニー インコーポレーテッド 片頭痛の治療方法及び医薬組成物
JP2012526849A (ja) 2009-05-13 2012-11-01 サイデックス・ファーマシューティカルズ・インコーポレイテッド プラスグレル及びシクロデキストリン誘導体を含む医薬組成物並びにその製造方法及び使用方法
JP2018508570A (ja) 2015-11-25 2018-03-29 アクスサム セラピューティクス インコーポレイテッド メロキシカムを含む医薬組成物
WO2018129220A1 (fr) 2017-01-04 2018-07-12 Axsome Therapeutics, Inc. Compositions pharmaceutiques contenant du méloxicam
WO2018209150A1 (fr) 2017-05-10 2018-11-15 Axsome Therapeutics, Inc. Compositions pharmaceutiques contenant du méloxicam

Also Published As

Publication number Publication date
PE20212157A1 (es) 2021-11-09
CR20210420A (es) 2021-12-22
CL2021002070A1 (es) 2022-04-01
SG11202107926XA (en) 2021-08-30
CA3128940C (fr) 2023-11-07
AU2020218253B2 (en) 2023-02-23
JP2023062144A (ja) 2023-05-02
WO2020163620A1 (fr) 2020-08-13
KR20210118880A (ko) 2021-10-01
AU2023202545A1 (en) 2023-05-18
JP2024026732A (ja) 2024-02-28
JP2022519670A (ja) 2022-03-24
MX2021009435A (es) 2021-09-10
EP3920909A4 (fr) 2022-11-30
CA3213549A1 (fr) 2020-08-13
AU2020218253A1 (en) 2021-08-12
ECSP21060962A (es) 2021-11-30
BR112021015467A2 (pt) 2021-10-05
MA54904A (fr) 2021-12-15
IL285389A (en) 2021-09-30
EP3920909A1 (fr) 2021-12-15
CO2021010380A2 (es) 2021-09-30
CA3128940A1 (fr) 2020-08-13
JP7420990B2 (ja) 2024-01-23
CN113423397A (zh) 2021-09-21

Similar Documents

Publication Publication Date Title
US11426414B2 (en) Pharmaceutical compositions comprising meloxicam
US10894053B2 (en) Pharmaceutical compositions comprising meloxicam
US10940153B2 (en) Pharmaceutical compositions comprising meloxicam
US10799588B2 (en) Pharmaceutical compositions comprising meloxicam
US11013806B2 (en) Pharmaceutical compositions comprising meloxicam
US10780166B2 (en) Pharmaceutical compositions comprising meloxicam
US11266657B2 (en) Pharmaceutical compositions comprising meloxicam
US11020483B2 (en) Pharmaceutical compositions comprising meloxicam
US10933136B2 (en) Pharmaceutical compositions comprising meloxicam
US10758618B2 (en) Pharmaceutical compositions comprising meloxicam
US11110173B2 (en) Pharmaceutical compositions comprising meloxicam
US10821181B2 (en) Pharmaceutical compositions comprising meloxicam
US10780165B2 (en) Pharmaceutical compositions comprising meloxicam
US11433078B2 (en) Pharmaceutical compositions comprising meloxicam
US20200376124A1 (en) Pharmaceutical compositions comprising meloxicam
US20200261467A1 (en) Pharmaceutical compositions comprising meloxicam
US11628173B2 (en) Pharmaceutical compositions comprising meloxicam
US11944683B2 (en) Pharmaceutical compositions comprising meloxicam
US20220096490A1 (en) Pharmaceutical compositions comprising meloxicam
US11602563B2 (en) Pharmaceutical compositions comprising meloxicam
US11806354B2 (en) Pharmaceutical compositions comprising meloxicam
US20230000879A1 (en) Pharmaceutical compositions comprising meloxicam
JP2023520574A (ja) メロキシカムを含む医薬組成物
JP2024026732A (ja) メロキシカムおよびリザトリプタンを含有する組み合わせの使用
US20240082254A1 (en) Pharmaceutical compositions comprising meloxicam

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20211122

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20211122

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20220922

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20221011

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20221130

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20230124

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20230221

R150 Certificate of patent or registration of utility model

Ref document number: 7237386

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150